Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Klebsiella phage JLBP1001
- Development stage
- Preclinical
- Lead developer
- Jinling Hospital
- Administration
- Intraperitoneal
01
Overview
Klebsiella phage JLBP1001 (JLBP1001) is a novel lytic bacteriophage belonging to the *Webervirus* genus of the *Drexlerviridae* family. It was isolated from hospital sewage by researchers at Nanjing University. JLBP1001 specifically targets carbapenem-resistant hypervirulent *Klebsiella pneumoniae* (CR-hvKP) clinical strains, particularly those of the ST218 KL57 capsular type. In preclinical studies using a mouse model of intra-abdominal infection (IAI), treatment with JLBP1001 significantly improved survival rates and reduced bacterial load, demonstrating its potential as a therapeutic agent for multidrug-resistant bacterial infections.
- Other names
- Klebsiella phage JLBP1001phage JLBP1001
02
Targets
K1 CPS (Klebsiella pneumoniae capsular polysaccharide serotype K1)
Beyond the preview
Go deeper on Klebsiella phage JLBP1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Klebsiella phage JLBP1001.